Verismo Therapeutics announced on the 6th that it presented the preclinical efficacy evaluation results of 'SynKIR-110' at the Society for Immunotherapy of Cancer Annual Meeting (SITC 2023), held in San Diego, USA, from the 1st to the 5th of this month.
Verismo is a US subsidiary of HLB, developing next-generation chimeric antigen receptor (CAR)-T cell therapies.
Dr. Laura Johnson and Dr. Jun Shu of Verismo presented the antitumor effects of the first mesothelin (MSLN)-targeting KIR-CAR T cell therapy (SynKIRTM-110) evaluated in an immunodeficient mouse (NSG) model implanted with patient-derived mesothelioma, which showed no anticancer effect with existing CAR T-cell therapies.
The company explained that Verismo's data demonstrated for the first time that the anticancer efficacy of SynKIR-110 varies according to the administered dose and shows differentiated efficacy compared to the MSLN-41BBz CAR-T cell therapy previously evaluated in clinical trials.
Additionally, through histopathological analysis, SynKIR-110 showed enhanced efficacy in primary tumor sites and metastatic sites, and it was confirmed that no toxicity occurred regardless of CAR or KIR-CAR treatment, the company added.
The company stated that these data are expected to technically support the ongoing Phase 1 clinical trial of SynKIR-110 in patients with solid tumors.
Meanwhile, the HLB Group expanded its pipeline into the CAR-T therapy field when HLB and HLB Pharm became the largest shareholders of Verismo through investment in 2021. Since then, HLB Innovation has further acquired Verismo shares, strengthening clinical support and collaboration.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
